1. Skip to navigation
  2. Skip to content
  3. Skip to sidebar


  • Jeffrey R. Jasper, Ph.D.

    Co-founder, Advisor

    Jeffrey R. Jasper, Ph.D., is currently a pharmacology consultant at Altos Therapeutics. Dr. Jasper completed his bachelor’s training in Chemistry at Cal Poly University and received his Ph.D. in Pharmacology from the University of California, San Diego studying receptor/G-protein signaling. His postdoctoral training at Stanford University also revolved primarily around receptor signaling mechanisms. Dr. Jasper was subsequently on staff at Stanford and taught undegraduate courses while cloning and sequencing the mouse beta-1 adrenoceptor to construct the initial beta-1 knock-out mice. In 1993 he became a senior research pharmacologist at Merck Research Laboratories and later was a research scientist at Roche Palo Alto. Dr. Jasper was Senior Director of Molecular and Cellular Biochemistry at Theravance, Inc., Department Head of Pharmacology at ARYx Therapeutics and is currently Vice President, Preclinical Sciences, at Revolution Medicines. Dr. Jasper has led numerous programs at the research stage as well as Phase 1-Phase 3 clinical stage projects and he also taught Molecular Pharmacology for UC Berkeley Extension for 13 years. While at ARYx Therapeutics, Dr. Jasper led the program that resulted in ATC-1906.

  • Richard Clark

    Co-founder, Advisor

    Richard Clark is Senior Director of Biopharma Strategy at Medtronic. Richard was previously Senior Director, Commercial at ARYx Therapeutics, where worked on gastroenterology programs including the pro-motility agent naronapride. Richard served on the joint steering committee with Proctor & Gamble, leading naronapride’s Phase II development and life cycle planning. At ARYx, Richard managed portfolio planning, asset valuation, and business development Prior to ARYx, Richard worked at Genentech in sales, marketing, product development, and market access. He has a Bachelor's of Science from Missouri State University.

  • Steven Pikulin Ph.D. RAC

    Advisor

    Steven Pikulin is handling Alto Therapeutics’ CMC plan. Dr. Pikulin is currently the president of TechReg Services Inc (TRSI) and has personally written well over one hundred domestic and international new drug, biologic and generic CMC submissions for over 50 different healthcare companies across a wide variety of dosage forms. His role in these projects usually involved complete management of CMC development as well as preparation of the corresponding regulatory documentation, cGMP compliance audits and interaction with the regulatory agencies. Dr. Pikulin his B.A. degree in Chemistry from Hofstra University and his M.S., M. Phil. and Ph.D. degrees in Physical Organic Chemistry from Yale University. Prior to founding TRSI in 1999, he held various positions in over 20 years in the pharmaceutical industry in Drug Discovery, Manufacturing Operations, Analytical Research, Quality Control, Quality Assurance, and CMC Regulatory Affairs. He has presented to the FDA and non-US regulatory agencies on a number of CMC related topics.

  • Bonnie Bowers

    Advisor

    Bonnie Bowers oversees project management at Altos. Her experience includes projects ranging in stage from research through Phase 3 clinical trials, registration, manufacturing process validation, and production of launch supplies and she brings over 22 years of project management experience in the pharmaceutical and biotechnology industries, including Genencor, Roche Bioscience, CV Therapeutics, and Syntex, as well as consulting assignments at ROXRO Pharma, Exelixis, and Gilead. Ms Bowers received her B.S. in Animal Science from University of California, Davis and her M.S. in Animal Science from Cornell University.

  • Tom M. Moran

    Advisor

    Presently Mr. Moran is an IP consultant for Fenwick & West LLP and several other independent clients. He is a founder of Scheiman Rebuild Fitness, Inc. and Camptologics, Inc., both startup companies in which he is playing a key role. Prior to Tom’s association with these companies, he was Special Counsel at Foley & Lardner LLP, where he dealt with all aspects of developing, evaluating, and protecting intellectual property regarding inventions for pharmaceutical-related and medical device products until his retirement in 2008. Prior to working at Foley & Lardner, Tom was Special Counsel at Cooley LLP from 1994 till 2005 where he handled all aspects of IP for numerous small bio-pharmaceutical, diagnostic, and medical device companies, including drafting, prosecuting, and appealing patent applications; licensing IP; providing due diligence analysis of IP associated with mergers, acquisitions, and public offerings; and litigation support. In addition he worked with several universities and non-profit organizations to expand their patent portfolios. Prior to working at Cooley, Tom worked at Syntex Corporation in the Legal Affairs Department for 19 years where he spent his last several years as the Director of the Patent Department for the US Pharmaceuticals Group. During his time at Syntex he was involved in protecting all aspects of Syntex’ IP as it related to the research, development, and marketing of Syntex’ projects and products. Tom has a degree in Chemistry from Beloit College and a JD from Golden Gate University, which obtained at night while working full time as a patent agent for Shell Oil Company. He was on the Board of Directors of the YMCA of the Midpeninsula from1980 to 1986 when he was involved in the planning and fund raising for Phase I of the El Camino Branch of the YMCA in Mountain View, CA. In 1987 he joined the new Board of Directors for the El Camino branch, which opened in 1989. He later chaired the campaign to raise $3,000,000.00 to expand the facility. Tom is still on the Y Board.

Have questions?

Contact us with questions or comments.

Contact us now